Raul Villa, MD Mph
About Raul Villa, MD Mph
Raul Villa, MD MPH, serves as the Vice President and Global Head of Drug Safety and Pharmacovigilance at Insmed Incorporated. He has extensive experience in the pharmaceutical industry, having held key positions at several major companies over the past two decades.
Current Role at Insmed
Raul Villa serves as the Vice President and Global Head of Drug Safety and Pharmacovigilance at Insmed Incorporated. He has held this position since 2019, contributing to the company's commitment to patient safety and regulatory compliance. His role involves overseeing drug safety operations and ensuring effective pharmacovigilance practices within the organization.
Previous Experience in Drug Safety
Before joining Insmed, Raul Villa held several significant positions in the field of drug safety and pharmacovigilance. He worked at Theravance Biopharma US, Inc. as Head of Clinical Safety and Pharmacovigilance from 2014 to 2019. Prior to that, he was the Senior Medical Director for Global Pharmacovigilance and Medical Risk Management at Cubist Pharmaceuticals from 2011 to 2014. His experience spans various roles that emphasize the importance of safety in clinical development.
Career at Sanofi-Aventis
Raul Villa worked at Sanofi-Aventis from 2000 to 2007 as a Global Safety Officer. During his seven years in this role, he was based in Bridgewater, NJ. His responsibilities included managing global safety data and ensuring compliance with regulatory requirements, which laid the foundation for his future roles in drug safety.
Educational Background
Raul Villa holds a Bachelor of Science degree from the University of Santo Tomas, where he completed an accelerated program. He also earned a Doctor of Medicine (MD) degree from the same university. Additionally, he studied Epidemiology at Rutgers University, obtaining a Master of Public Health (MPH). His educational background supports his expertise in clinical risk management and pharmacovigilance.
Experience in Clinical Risk Management
Raul Villa has extensive experience in clinical risk management, having served as the Director of Clinical Risk Management at Merck from 2009 to 2011. In this role, he was responsible for identifying and mitigating risks associated with clinical trials and drug development. His expertise in this area has been instrumental in shaping safety protocols in the pharmaceutical industry.